619 related articles for article (PubMed ID: 9457238)
1. Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
Chan C; Yin H; Garforth J; McKie JH; Jaouhari R; Speers P; Douglas KT; Rock PJ; Yardley V; Croft SL; Fairlamb AH
J Med Chem; 1998 Jan; 41(2):148-56. PubMed ID: 9457238
[TBL] [Abstract][Full Text] [Related]
2. Peptoid inhibition of trypanothione reductase as a potential antitrypanosomal and antileishmanial drug lead.
Chan C; Yin H; McKie JH; Fairlamb AH; Douglas KT
Amino Acids; 2002 Jun; 22(4):297-308. PubMed ID: 12107758
[TBL] [Abstract][Full Text] [Related]
3. Assaying phenothiazine derivatives as trypanothione reductase and glutathione reductase inhibitors by theoretical docking and molecular dynamics studies.
Iribarne F; Paulino M; Aguilera S; Tapia O
J Mol Graph Model; 2009 Nov; 28(4):371-81. PubMed ID: 19801198
[TBL] [Abstract][Full Text] [Related]
4. Irreversible inactivation of trypanothione reductase by unsaturated Mannich bases: a divinyl ketone as key intermediate.
Lee B; Bauer H; Melchers J; Ruppert T; Rattray L; Yardley V; Davioud-Charvet E; Krauth-Siegel RL
J Med Chem; 2005 Nov; 48(23):7400-10. PubMed ID: 16279799
[TBL] [Abstract][Full Text] [Related]
5. Use of an additional hydrophobic binding site, the Z site, in the rational drug design of a new class of stronger trypanothione reductase inhibitor, quaternary alkylammonium phenothiazines.
Khan MO; Austin SE; Chan C; Yin H; Marks D; Vaghjiani SN; Kendrick H; Yardley V; Croft SL; Douglas KT
J Med Chem; 2000 Aug; 43(16):3148-56. PubMed ID: 10956223
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and evaluation of 2,4-diaminoquinazolines as inhibitors of trypanosomal and leishmanial dihydrofolate reductase.
Khabnadideh S; Pez D; Musso A; Brun R; Pérez LM; González-Pacanowska D; Gilbert IH
Bioorg Med Chem; 2005 Apr; 13(7):2637-49. PubMed ID: 15755663
[TBL] [Abstract][Full Text] [Related]
7. Antitrypanosomal, antileishmanial, and antimalarial activities of quaternary arylalkylammonium 2-amino-4-chlorophenyl phenyl sulfides, a new class of trypanothione reductase inhibitor, and of N-acyl derivatives of 2-amino-4-chlorophenyl phenyl sulfide.
Parveen S; Khan MO; Austin SE; Croft SL; Yardley V; Rock P; Douglas KT
J Med Chem; 2005 Dec; 48(25):8087-97. PubMed ID: 16335933
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of phenothiazine- and phenoxazine-derived chloroacetamides on Leishmania major growth and Trypanosoma brucei trypanothione reductase.
Marcu A; Schurigt U; Müller K; Moll H; Krauth-Siegel RL; Prinz H
Eur J Med Chem; 2016 Jan; 108():436-443. PubMed ID: 26708110
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design.
Aguirre G; Cabrera E; Cerecetto H; Di Maio R; González M; Seoane G; Duffaut A; Denicola A; Gil MJ; Martínez-Merino V
Eur J Med Chem; 2004 May; 39(5):421-31. PubMed ID: 15110968
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for the antileishmanial and antitrypanosomal activities of 1'-substituted 9-anilinoacridines.
Gamage SA; Figgitt DP; Wojcik SJ; Ralph RK; Ransijn A; Mauel J; Yardley V; Snowdon D; Croft SL; Denny WA
J Med Chem; 1997 Aug; 40(16):2634-42. PubMed ID: 9258370
[TBL] [Abstract][Full Text] [Related]
11. [Inactivation of Trypanosoma cruzi trypanothione reductase by phenothiazine cationic free radicals].
Gutierrez Correa J; Fairlamb AH; Stoppani AO
Rev Argent Microbiol; 2001; 33(1):36-46. PubMed ID: 11407019
[TBL] [Abstract][Full Text] [Related]
12. Synthesis, inhibition potency, binding mode, and antiprotozoal activities of fluorescent inhibitors of trypanothione reductase based on mepacrine-conjugated diaryl sulfide scaffolds.
Eberle C; Burkhard JA; Stump B; Kaiser M; Brun R; Krauth-Siegel RL; Diederich F
ChemMedChem; 2009 Dec; 4(12):2034-44. PubMed ID: 19847846
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of 9,9-dimethylxanthene tricyclics against trypanothione reductase, Trypanosoma brucei, Trypanosoma cruzi and Leishmania donovani.
Chibale K; Visser M; Yardley V; Croft SL; Fairlamb AH
Bioorg Med Chem Lett; 2000 Jun; 10(11):1147-50. PubMed ID: 10866368
[TBL] [Abstract][Full Text] [Related]
14. Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures.
Benson TJ; McKie JH; Garforth J; Borges A; Fairlamb AH; Douglas KT
Biochem J; 1992 Aug; 286 ( Pt 1)(Pt 1):9-11. PubMed ID: 1355650
[TBL] [Abstract][Full Text] [Related]
15. Crystal structure of the Trypanosoma cruzi trypanothione reductase.mepacrine complex.
Jacoby EM; Schlichting I; Lantwin CB; Kabsch W; Krauth-Siegel RL
Proteins; 1996 Jan; 24(1):73-80. PubMed ID: 8628734
[TBL] [Abstract][Full Text] [Related]
16. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.
Stoll VS; Simpson SJ; Krauth-Siegel RL; Walsh CT; Pai EF
Biochemistry; 1997 May; 36(21):6437-47. PubMed ID: 9174360
[TBL] [Abstract][Full Text] [Related]
17. Chinifur, a selective inhibitor and "subversive substrate" for Trypanosoma congolense trypanothione reductase.
Cenas N; Bironaite D; Dickancaite E; Anusevicius Z; Sarlauskas J; Blanchard JS
Biochem Biophys Res Commun; 1994 Oct; 204(1):224-9. PubMed ID: 7945363
[TBL] [Abstract][Full Text] [Related]
18. Binding to large enzyme pockets: small-molecule inhibitors of trypanothione reductase.
Persch E; Bryson S; Todoroff NK; Eberle C; Thelemann J; Dirdjaja N; Kaiser M; Weber M; Derbani H; Brun R; Schneider G; Pai EF; Krauth-Siegel RL; Diederich F
ChemMedChem; 2014 Aug; 9(8):1880-91. PubMed ID: 24788386
[TBL] [Abstract][Full Text] [Related]
19. Toward the development of dual-targeted glyceraldehyde-3-phosphate dehydrogenase/trypanothione reductase inhibitors against Trypanosoma brucei and Trypanosoma cruzi.
Belluti F; Uliassi E; Veronesi G; Bergamini C; Kaiser M; Brun R; Viola A; Fato R; Michels PA; Krauth-Siegel RL; Cavalli A; Bolognesi ML
ChemMedChem; 2014 Feb; 9(2):371-82. PubMed ID: 24403089
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis of antimony treatment in leishmaniasis.
Baiocco P; Colotti G; Franceschini S; Ilari A
J Med Chem; 2009 Apr; 52(8):2603-12. PubMed ID: 19317451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
